logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Advanced NSCLC: chemotherapy+ICIs boosts first-line efficacy

Efficacy especially enhanced with pembrolizumab or atezolizumab.